M Pachl1, G S Arul1, I Jester1, C Bowen2, D Hobin3, B Morland3. 1. Department of Paediatric Surgery and Urology, Birmingham Children's Hospital, Birmingham, UK. 2. Department of Histopathology, Birmingham Children's Hospital, Birmingham, UK. 3. Oncology Department, Birmingham Children's Hospital, Birmingham, UK.
Abstract
BACKGROUND: Congenital mesoblastic nephroma is a rare disease. Treatment is surgical in the first instance. Chemotherapy has traditionally been thought not to have a role. Recent literature suggests a 50% mortality rate for recurrent/metastatic disease. MATERIALS AND METHODS: This study is a retrospective case review of prospectively collected data. Demographics, histopathology, treatment, outcomes and follow up were reviewed. RESULTS: Nine patients, 6 male and 3 female, were included. The median age at presentation was one month (range 0-7 months); follow-up was for a median of 21.5 months (range 16-79 months). Two patients had mixed and classical subtypes and the other five had the cellular subtype. Surgery was completed by an open procedure in eight patients and laparoscopically in one. There were three recurrences; two were local and one was pulmonary. Recurrences were treated with a combination of chemotherapy, radiotherapy and surgery. One patient with recurrent disease died from acute-on-chronic respiratory failure secondary to lung irradiation but was disease free. The other eight are disease free, alive and well with no sequelae at latest follow-up. CONCLUSIONS: Surgery remains the mainstay of management with chemo- and radiotherapy reserved for unresectable tumours or adjuvant management of recurrent disease. Specimen-positive margins are not an indication for instituting chemotherapy. The tyrosine kinase pathway seems to be a potential target for future chemotherapeutic agents although it is too early to assess how that will impact on the management of congenital mesoblastic nephroma.
BACKGROUND:Congenital mesoblastic nephroma is a rare disease. Treatment is surgical in the first instance. Chemotherapy has traditionally been thought not to have a role. Recent literature suggests a 50% mortality rate for recurrent/metastatic disease. MATERIALS AND METHODS: This study is a retrospective case review of prospectively collected data. Demographics, histopathology, treatment, outcomes and follow up were reviewed. RESULTS: Nine patients, 6 male and 3 female, were included. The median age at presentation was one month (range 0-7 months); follow-up was for a median of 21.5 months (range 16-79 months). Two patients had mixed and classical subtypes and the other five had the cellular subtype. Surgery was completed by an open procedure in eight patients and laparoscopically in one. There were three recurrences; two were local and one was pulmonary. Recurrences were treated with a combination of chemotherapy, radiotherapy and surgery. One patient with recurrent disease died from acute-on-chronic respiratory failure secondary to lung irradiation but was disease free. The other eight are disease free, alive and well with no sequelae at latest follow-up. CONCLUSIONS: Surgery remains the mainstay of management with chemo- and radiotherapy reserved for unresectable tumours or adjuvant management of recurrent disease. Specimen-positive margins are not an indication for instituting chemotherapy. The tyrosine kinase pathway seems to be a potential target for future chemotherapeutic agents although it is too early to assess how that will impact on the management of congenital mesoblastic nephroma.
Entities:
Keywords:
Chemotherapy; Mesoblastic nephroma; Radiotherapy; Surgery
Authors: Sarah Whittle; Ankush Gosain; Petagay Y Scott Brown; Lairsa Debelenko; Susana Raimondi; Judith A Wilimas; Jesse J Jenkins; Andrew M Davidoff Journal: Pediatr Blood Cancer Date: 2010-08 Impact factor: 3.167
Authors: Rhoikos Furtwaengler; Harald Reinhard; Ivo Leuschner; Jens P Schenk; Ulrich Goebel; Alexander Claviez; Andreas Kulozik; Andreas Zoubek; Dietrich von Schweinitz; Norbert Graf Journal: Cancer Date: 2006-05-15 Impact factor: 6.860
Authors: Alanna J Church; Monica L Calicchio; Valentina Nardi; Alena Skalova; Andre Pinto; Deborah A Dillon; Carmen R Gomez-Fernandez; Namitha Manoj; Josh D Haimes; Joshua A Stahl; Filemon S Dela Cruz; Sarah Tannenbaum-Dvir; Julia L Glade-Bender; Andrew L Kung; Steven G DuBois; Harry P Kozakewich; Katherine A Janeway; Antonio R Perez-Atayde; Marian H Harris Journal: Mod Pathol Date: 2017-11-03 Impact factor: 7.842
Authors: Gang Wu; Alexander K Diaz; Barbara S Paugh; Sherri L Rankin; Bensheng Ju; Yongjin Li; Xiaoyan Zhu; Chunxu Qu; Xiang Chen; Junyuan Zhang; John Easton; Michael Edmonson; Xiaotu Ma; Charles Lu; Panduka Nagahawatte; Erin Hedlund; Michael Rusch; Stanley Pounds; Tong Lin; Arzu Onar-Thomas; Robert Huether; Richard Kriwacki; Matthew Parker; Pankaj Gupta; Jared Becksfort; Lei Wei; Heather L Mulder; Kristy Boggs; Bhavin Vadodaria; Donald Yergeau; Jake C Russell; Kerri Ochoa; Robert S Fulton; Lucinda L Fulton; Chris Jones; Frederick A Boop; Alberto Broniscer; Cynthia Wetmore; Amar Gajjar; Li Ding; Elaine R Mardis; Richard K Wilson; Michael R Taylor; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker Journal: Nat Genet Date: 2014-04-06 Impact factor: 38.330